All Products

Featured Products

Newest Products

Research Areas

NU-7200

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406412

CAS#: 842122-14-9

Description: NU-7200 is a potent DNA-PK inhibitor with potential anticancer activity.


Price and Availability

Size
Price
Size
Price
Size
Price

NU-7200 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406412
Name: NU-7200
CAS#: 842122-14-9
Chemical Formula: C17H17NO4
Exact Mass: 299.11576
Molecular Weight: 299.32118
Elemental Analysis: C, 68.21; H, 5.72; N, 4.68; O, 21.38


Synonym: NU-7200; NU 7200; NU7200.

IUPAC/Chemical Name: 2-((2-(2-hydroxyethoxy)ethyl)amino)-4H-benzo[h]chromen-4-one

InChi Key: UQJNMNYCRLPGSK-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H17NO4/c19-8-10-21-9-7-18-16-11-15(20)14-6-5-12-3-1-2-4-13(12)17(14)22-16/h1-6,11,18-19H,7-10H2

SMILES Code: O=C1C=C(NCCOCCO)OC2=C1C=CC3=CC=CC=C32


Technical Data

Appearance:
solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

 1. Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GC, Martin NM, Workman P, Raynaud FI. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br. J. Cancer (2005).